Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Capricor Therapeutics Inc CAPR

Healthcare Biotechnology
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product... see more

Recent & Breaking News (NDAQ:CAPR)

Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire August 6, 2019

Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6

GlobeNewswire July 30, 2019

Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy

GlobeNewswire July 25, 2019

Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy

GlobeNewswire July 17, 2019

Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy

GlobeNewswire July 15, 2019

Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2019

Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13

GlobeNewswire May 6, 2019

Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

GlobeNewswire March 28, 2019

Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28

GlobeNewswire March 21, 2019

Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy

GlobeNewswire February 6, 2019

Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy

GlobeNewswire January 24, 2019

Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA

GlobeNewswire January 22, 2019

Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals — New Research Emphasizes Economic Growth

GlobeNewswire December 27, 2018

Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire November 28, 2018

Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire November 13, 2018

Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial

GlobeNewswire November 12, 2018

Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference

GlobeNewswire November 8, 2018

Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13

GlobeNewswire November 6, 2018

Capricor Therapeutics to Provide Corporate Update at BIO-Europe Conference on Nov. 6

GlobeNewswire November 2, 2018

Capricor Therapeutics to Participate in Upcoming Conferences  

GlobeNewswire October 22, 2018